Malignant Melanoma
Conditions
Keywords
HF10, HSV-1, Ipilimumab, Oncolytic virus, Phase II, Stage IIIB melanoma, Stage IIIC melanoma, Stage IV melanoma, Unresectable malignant melanoma, Metastatic malignant melanoma, Combination treatment, Intratumoral injection
Brief summary
The purpose of this study is to determine if HF10 in combination with ipilimumab is effective in patients with stages IIIB, IIIC, or IV unresectable or metastatic melanoma.
Detailed description
The study is designed to assess efficacy and safety with repeated administration of intratumoral injections of HF10 at 1x10\^7 TCID50/mL in combination with intravenous infusions of 3mg/kg ipilimumab. This is a single arm, open label Phase II trial, to evaluate the efficacy, safety and tolerability of HF10 treatment in combination with administration of the immunologic checkpoint inhibitor, ipilimumab (anti-CTLA-4 monoclonal antibody). The study population will include patients with Stage IIIB, IIIC or IV unresectable or metastatic malignant melanoma who are ipilimumab-eligible. Patients will receive the dose of 1 x 10\^7 TCID50/mL HF10 (for a total of 6 injections; the first 4 injections at 1-week intervals; the remaining 2 injections at 3-week intervals) + ipilimumab at 3 mg/kg ipilimumab (for a total of 4 intravenous infusions, each administered at 3-week intervals). Following combination therapy, patients may continue to receive the same dose level of HF10 (1 x 10\^7 TCID50/mL) alone for up to an additional 13 injections (total of 19 injections = 1 year) if they have tolerated the study treatment, are responding, have stable disease, or have progressive disease that is not clinically significant in the judgment of the Investigator.
Interventions
BIOLOGICALHF10 plus Ipilimumab
Patients will receive the dose of 1 x 10\^7 TCID50/mL HF10 (for a total of 6 injections; the first 4 injections at 1-week intervals; the remaining 2 injections at 3-week intervals) and ipilimumab at 3 mg/kg ipilimumab (for a total of 4 intravenous infusions, each administered at 3-week intervals).
Sponsors
Theradex
Takara Bio Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients must have Stage IIIB, IIIC or IV melanoma, which is unresectable/unresected or histologically confirmed diagnosis of metastatic malignant melanoma. 2. Patients must have measurable non-visceral lesion(s) that are evaluable by the modified World Health Organization (mWHO) criteria and immune-related response criteria (irRC). 3. Patients must be ≥ 18 years of age. 4. Patients must have a life expectancy ≥ 24 weeks. 5. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. 6. Patients must have adequate hepatic function, defined as * Total bilirubin levels ≤ 1.5 x upper limit of normal \[ULN\] (except for patients with Gilbert's Syndrome, who must have a total bilirubin of less than 3.0 mg/dL) * AST/ALT levels ≤ 2.5 x ULN, or ≤ 5 x ULN if liver metastases are present. 7. Patients must have adequate renal function, defined as serum creatinine ≤ 1.5 x ULN or creatinine clearance (calculated) ≥ 60 mL/min/1.73 m2 for patients with creatinine \> 1.5 x ULN. 8. Patients must have adequate bone marrow function, defined as * Absolute neutrophil count ≥1,500/µL and * Platelet count ≥ 75,000/ µL 9. Patients must have no known bleeding diathesis or coagulopathy that would make intratumoral injection or biopsy unsafe. 10. Patients must be ipilimumab-eligible. (This includes: 1) patients previously untreated with ipilimumab; 2) patients previously treated (more than 1 year previously) with ipilimumab using a route of administration other than intravenous infusion; and 3) patients previously treated with antitumor agents other than intravenous ipilimumab). 11. Men and women of childbearing potential must agree to use adequate contraception from the time of consent through 30 days after final study treatment. 12. Females of childbearing potential must have a negative urine or serum pregnancy test within one week prior to start of treatment. 13. Patients must be able to understand and willing to sign a written informed consent document.
Exclusion criteria
1. Patients receiving chemotherapy or radiotherapy within 4 weeks of injection of HF10, or history of Grade 4 adverse events or presence of adverse events Grade 2 or greater, except alopecia, resulting from anticancer agents administered more than 4 weeks prior to HF10 injection. 2. Patients receiving anti-herpes medication within 1 week prior to initiating HF10 treatment. 3. Patients with a history of significant tumor bleeding, or coagulation or bleeding disorders. 4. Patients with target tumors that could potentially invade a major vascular structure (e.g., innominate artery, carotid artery), based on unequivocal imaging findings. 5. Patients with Grade 2 or greater pre-existing neurologic abnormalities (CTCAE version 4.0), including Grade 2 or greater peripheral neuropathy caused by previous treatments. 6. Patients with clinically evident Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C virus (HCV), or Epstein-Barr virus (EBV) infection are excluded. 7. Medical history of autoimmune disease (e.g., Crohn's disease, ulcerative colitis) or other diseases requiring systemic glucocorticoid or immunosuppressive therapy. 8. Patients who were previously treated with ipilimumab administered by intravenous infusion. 9. Concurrent use of any other investigational agents. 10. Patients with active CNS metastases or carcinomatous meningitis, except patients with CNS lesions that have been treated and have no evidence of progression in the brain on CT/MRI for ≥ 3 months. 11. Pregnant or breastfeeding women; women desiring to become pregnant within the timeframe of the study are also excluded. 12. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements, as determined by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Best overall response rate (BORR) | at 24 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate (ORR) | at Weeks 12, 18, and 24 | — |
| Progression-free survival (PFS) | for 1 year | — |
| Durable response rate (DRR) | for 1 year | — |
| Adverse Event Summaries, Vital Signs, and Laboratory Parameters as a Measure of Safety and Tolerability | until Week 24 | Adverse events will be evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE version 4.0). |
| Accumulation of Lymphocytes in the Tumor by using Core Biopsy Samples | pre-treatment screening and Week 24 | — |
| Change in Cytokine Profiles by using Peripheral Blood Samples | pre-treatment screening and Week 24 | — |
| 1-year survival rate | at 1 year | — |
Countries
United States
Outcome results
None listed